DVAX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Dynavax Technologies Corporation and a Lead Plaintiff Deadline of January 17, 2017

NEW YORK, Jan. 3, 2017 /PRNewswire/ -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased Dynavax Technologies Corporation (NASDAQ: DVAX) securities between March 10, 2014 and November 11, 2016.

Click here to learn about the case: http://www.wongesq.com/pslra/dynavax-technologies-corporation. There is no cost or obligation to you.

According to the complaint, during the Class Period Dynavax made false and/or misleading statements and/or failed to disclose that: (i) the phase 3 HBV-23 trial for the Company's lead vaccine product HEPLISAV-B was not designed in accordance with the U.S. Food and Drug Administration's concerns and issues, as pointed out in a 2013 Complete Response Letter; (ii) Dynavax failed to provide sufficient information to the FDA in its Revised Biologics License Application for the drug; (iii) Dynavax's resources will not be sufficient for the Company to advance the HEPLISAV-B program on its own; and (iv) as a result of the foregoing, the Company's financial statements, as well as Defendants' statements about Dynavax's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

If you suffered a loss in Dynavax you have until January 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/dynavax-technologies-corporation.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights.  Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:    
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dvax-investor-alert-the-law-offices-of-vincent-wong-reminds-investors-of-a-class-action-involving-dynavax-technologies-corporation-and-a-lead-plaintiff-deadline-of-january-17-2017-300384731.html

SOURCE The Law Offices of Vincent Wong